MarketCapExport financials
Genetic Technologies Limited (GENE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Genetic Technologies Limited Income Statement 2024-2011 | GENE
Brief overview of revenue and earnings at Genetic Technologies Limited
The figures are compared over a five-year interval. Revenue at Genetic Technologies Limited moved from 25.4 thousand AUD in 2019 to 7.7 million AUD in 2024. The five-year change reached +30024.1%, while CAGR stood at 213.2%. The annual growth rate indicates an exceptionally strong top-line trend.
The five-year EBITDA result moved by +100%: from −6 million AUD to 0 AUD. EBITDA underperformed the top-line trend. Comparing the endpoints gives EBITDA margins of −23573.7% and 0%. Higher profitability strengthens the quality of operating growth.
The net financial result changed from −6.4 million AUD to −12 million AUD. The negative result deepened, showing weaker final efficiency.
Conclusion
The figures do not all move in the same direction. The strongest signals are an improving EBITDA margin and a larger revenue base. Caution is warranted because of lower net income and limited operating profitability. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Genetic Technologies Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | - | 133 M | 17.7 B | 18.2 B | 7.35 B | 8.38 B | 12.2 B | 7.55 B | 24.4 M | 17.4 M | 40.1 M | 57.6 M | 81.5 M |
Shares |
132 M | 101 M | 92.2 M | 8.54 B | 4.16 B | 2.64 B | 2.44 B | 2.12 B | 1.72 B | 1.92 M | 1.03 M | 843 K | 822 K | 723 K |
Historical Prices |
- | - | 1.44 | 2.07 | 4.37 | 2.79 | 3.44 | 5.76 | 4.4 | 8.24 | 23.3 | 32.8 | 49 | 63.6 |
Net Income |
-12 M | -11.8 M | -7.13 M | -7.08 M | -6.29 M | -6.43 M | -5.46 M | -8.4 M | -8.46 M | -8.81 M | -10.1 M | -9.3 M | -5.29 M | 910 K |
Revenue |
7.66 M | 8.69 M | 6.79 M | 121 K | 9.86 K | 25.4 K | 189 K | 519 K | 825 K | 2.01 M | 4.56 M | 3.38 M | 3.69 M | 18.3 M |
Cost of Revenue |
- | - | - | 361 K | 252 K | 276 K | 300 K | 492 K | 743 K | - | - | - | - | - |
Gross Profit |
- | - | - | -240 K | -242 K | -251 K | -111 K | 26.1 K | 81.5 K | 1.12 M | 2.73 M | 1.43 M | 1.74 M | 16.2 M |
Interest Expense |
17.6 K | 29.5 K | 15.2 K | 16.3 K | 37.4 K | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | -6 M | -5.67 M | -7.55 M | -8.17 M | -9.52 M | -9.51 M | -8.75 M | -10.5 M | 1.66 M |
Operating Expenses |
- | - | - | - | - | 5.91 M | 5.87 M | 7.94 M | 8.64 M | 10.9 M | 12.6 M | 10.6 M | 12.8 M | 15.2 M |
General and Administrative Expenses |
- | - | - | 4.16 M | 4.06 M | 3.83 M | 3.02 M | 3.11 M | 3.43 M | 4.66 M | 4.25 M | 6.81 M | 6.88 M | 7.79 M |
All numbers in AUD currency
Quarterly Income Statement Genetic Technologies Limited
| 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
132 M | 115 M | 101 M | 9.23 B | - | 92.2 M | - | - | - | 8.54 B | - | - | - | 4.16 B | - | - | - | 2.64 B | - | - | - | 2.44 B | - | - | - | 2.12 B | - | - | - | 1.72 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-12 M | -6.42 M | -11.8 M | -5.46 M | - | -7.13 M | - | - | - | -7.08 M | - | - | - | -6.29 M | - | - | - | -6.43 M | - | - | - | -5.46 M | - | - | - | -8.4 M | - | - | - | -8.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
7.66 M | 3.96 M | 8.69 M | 4.15 M | - | 6.79 M | - | - | - | 121 K | - | - | - | 9.86 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
- | - | - | - | - | - | - | - | - | 361 K | - | - | - | 252 K | - | - | - | 276 K | - | - | - | 300 K | - | - | - | 492 K | - | - | - | 743 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | -240 K | - | - | - | -242 K | - | - | - | -251 K | - | - | - | -111 K | - | - | - | 26.1 K | - | - | - | 81.5 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
- | - | - | - | - | - | - | - | - | - | - | - | - | -2.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
17.6 K | - | 29.5 K | - | - | 15.2 K | - | - | - | 16.3 K | - | - | - | 37.4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
- | - | - | - | - | - | - | - | - | - | - | - | - | -2.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | - | - | - | - | - | - | - | 4.16 M | - | - | - | 4.06 M | - | - | - | 3.83 M | - | - | - | 3.02 M | - | - | - | 3.11 M | - | - | - | 3.43 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in AUD currency
The income statement is one of the three key financial reports of a company Genetic Technologies Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
ICON Public Limited Company
ICLR
|
$ 168.33 | 3.88 % | $ 13.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 527.07 | 1.67 % | $ 42.4 B |  USA |
 |
Illumina
ILMN
|
$ 293.69 | 7.56 % | $ 45.5 B | USA |
 |
IQVIA Holdings
IQV
|
$ 266.09 | 3.05 % | $ 45.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 308.65 | 0.05 % | $ 25.7 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 100.19 | 0.23 % | $ 6.76 B | USA |
 |
Medpace Holdings
MEDP
|
$ 620.51 | 3.51 % | $ 17.9 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 541.63 | 3.73 % | $ 31.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.58 | 0.88 % | $ 424 M | USA |
 |
ENDRA Life Sciences
NDRA
|
$ 6.31 | 4.13 % | $ 4.97 M | USA |
 |
NeoGenomics
NEO
|
$ 19.13 | 3.57 % | $ 2.45 B | USA |
 |
Neogen Corporation
NEOG
|
$ 13.01 | 7.08 % | $ 2.83 B | USA |
 |
National Research Corporation
NRC
|
$ 20.78 | 2.11 % | $ 465 M | USA |
 |
Natera
NTRA
|
$ 425.64 | 3.73 % | $ 58.2 B | USA |
 |
OPKO Health
OPK
|
$ 1.57 | 0.64 % | $ 1.18 B | USA |
 |
Pacific Biosciences of California
PACB
|
$ 2.87 | 12.99 % | $ 861 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 23.91 | 0.04 % | $ 22.7 B |  Niderland |
 |
Precipio
PRPO
|
$ 24.0 | 3.76 % | $ 38.5 M | USA |
 |
Personalis
PSNL
|
$ 16.4 | 0.74 % | $ 1.46 B | USA |
 |
Quidel Corporation
QDEL
|
$ 12.14 | 12.72 % | $ 511 M | USA |
 |
QIAGEN N.V.
QGEN
|
$ 45.79 | 2.34 % | $ 9.95 B | Niderland |
 |
RadNet
RDNT
|
$ 70.63 | 1.0 % | $ 5.31 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.31 | 4.35 % | $ 430 M | USA |
 |
Sotera Health Company
SHC
|
$ 18.55 | 1.81 % | $ 5.27 B | USA |
 |
Neuronetics
STIM
|
$ 2.2 | 1.85 % | $ 145 M | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 676.76 | 3.35 % | $ 255 B | USA |
 |
Twist Bioscience Corporation
TWST
|
$ 205.0 | 8.66 % | $ 12.3 B | USA |
 |
VolitionRx Limited
VNRX
|
$ 0.23 | 0.35 % | $ 28.9 M |  Singapore |
 |
Waters Corporation
WAT
|
$ 440.12 | 3.51 % | $ 26.2 B | USA |
 |
Exagen
XGN
|
$ 8.46 | 3.55 % | $ 182 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |  Israel |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Brainsway Ltd.
BWAY
|
$ 12.23 | 1.35 % | $ 415 M | Israel |
 |
Trinity Biotech plc
TRIB
|
$ 5.77 | 1.41 % | $ 2.07 B | Irlanda |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | USA |